8 Amendments of Eleni THEOCHAROUS related to 2016/2096(INI)
Amendment 9 #
Draft opinion
Paragraph 1 b (new)
Paragraph 1 b (new)
1b. Notes that women are more vulnerable to mental illness due to the differences in power and control men and women have over the socioeconomic determinants of their mental health and lives, their social position, status and treatment in society and their susceptibility and exposure to specific mental health risks;
Amendment 11 #
Draft opinion
Paragraph 1 a (new)
Paragraph 1 a (new)
1a. Stresses that empowering women and promoting gender equality is crucial to accelerating sustainable development and thus, ending all forms of discrimination against women and girls, including those occurring in mental health and clinical research, is not only a basic human right, but it also has a multiplier effect across all other development areas (SDG5);
Amendment 18 #
Draft opinion
Paragraph 2 a (new)
Paragraph 2 a (new)
2a. Underlines that pressures created by women's multiple roles, gender discrimination and associated factors of poverty, hunger, malnutrition, overwork, domestic violence and sexual abuse, combine to account for women's poor mental health whereas in developing countries' most centres, these patients are not recognized and therefore not treated; while communication between health workers and women patients is extremely authoritarian, making a woman's disclosure of psychological and emotional distress difficult, and often stigmatized;
Amendment 19 #
Draft opinion
Paragraph 2 b (new)
Paragraph 2 b (new)
2b. Promoting, through lifelong education, the formulation and implementation of health policies that address women's needs and concerns from childhood to old age and enhancing the competence of primary health care providers to recognize and treat mental health consequences of domestic violence, sexual abuse, and acute and chronic stress in women is essential in order to address gender discrimination in health care;
Amendment 20 #
Draft opinion
Paragraph 2 c (new)
Paragraph 2 c (new)
2c. Notes that widening disparities among African countries are a call for action that require the adoption of sound policies to empower the bottom percentile of income earners and promote economic inclusion of all (SDG10); Income inequality is a global problem that requires global solutions by improving the regulation and monitoring of financial markets and institutions, encouraging development assistance and foreign direct investment to regions where the need is greatest, reducing to that effect gender discrimination and inequalities in the health sector;
Amendment 21 #
Draft opinion
Paragraph 3
Paragraph 3
3. Stresses the need to invest in global health research and development (R&D) to strengthen national health systems and to achieve universal healthcare coverage , also by pooling resources to complement national ones as well as with investments in local research tailored to each country's needs; regrets that the EU has not incorporated the principles of its global health policy into its innovation strategy; regrets also that there are no binding provisions in any of the mechanisms which ensure that Poverty- Related and Neglected Diseases (PRND) R&D funded through the EU will produce accessible, affordable, suitable and acceptable products for populations in resource-poor settings, or that research data will be openly accessible;
Amendment 31 #
Draft opinion
Paragraph 4
Paragraph 4
4. Notes with concern that the increase in offshoring medicine testing to Africa may result in serious ethical violations; points out that not having access to affordable healthcare or health insurance gives vulnerable people, particularly women, no other choice than to participate in clinical trials in order to receive medical treatment unaware of any risks entailed;
Amendment 32 #
Draft opinion
Paragraph 5
Paragraph 5
5. Calls on transnational pharmaceutical companies to fulfil their corporate responsibility to respect human rights, as enshrined in the United Nations Guiding Principles on Business and Human Rights (UNGPBHR), when engaging in clinical trials in low- and middle-income countries; deems that they should ensure the proper protection of participants’ safety and rights, and the conformity of their practices with the highest ethical standards. and international guidelines as set in the Declaration of Helsinki of the World Medical Association (DoH) as well as the CIOMS and WHO guidelines on Good Clinical Practice (GCP);